# Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

> **NCT01408160** · PHASE1 · TERMINATED · sponsor: **Albert Einstein College of Medicine** · enrollment: 18 (actual)

## Conditions studied

- Adult B Acute Lymphoblastic Leukemia
- Recurrent Adult Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Cytarabine
- **BIOLOGICAL:** Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01408160
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-04
- **Primary completion:** 2018-06-26
- **Final completion:** 2018-06-26
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01408160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01408160, "Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01408160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*